Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

5-methylcytosine regulated CCNL2 promotes tumorigenesis and cisplatin resistance of ovarian cancer with therapeutic implications

24 Jul 2025

Abstract excerpt

Ovarian cancer (OC) is the most lethal gynecological tumor, primarily due to resistance to chemotherapy. Cyclin L2 (CCNL2) is a novel member of the cyclin family and mainly localized in nucleus. It regulates transcription and alternative splicing by interacting with cyclin-dependent kinases. However, its role in OC chemoresistance remains unknown. Here, we demonstrated that the expression level of CCNL2 was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to RNA modifications and cancer
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40707993
DOI: 10.1186/s13048-025-01753-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5-methylcytosine regulated CCNL2 promotes tumorigenesis and cisplatin resistance of ovarian cancer with therapeutic implicationsPMID 40707993Read ↗

METTL2B m3C RNA Transferase: Oncogenic Role in Ovarian Cancer Progression and its Link to the Tumor Immune MicroenvironmentSemantic proximity Read ↗

Mitophagy-related long non-coding RNA signature predicts prognosis and drug response in Ovarian CancerSemantic proximity Read ↗

Combining Bioinformatics and Experiments to Identify MAD2L2 as a Key Regulator in Ovarian CancerSemantic proximity Read ↗

NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinomaSemantic proximity Read ↗

MAD2L2, a key regulator in ovarian cancer and promoting tumor progressionSemantic proximity Read ↗

Downregulated m⁵C Regulator NSUN6 Enhances Proliferation, Migration and affects immune regulation in Ovarian CancerSemantic proximity Read ↗

LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoterSemantic proximity Read ↗

Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancerSemantic proximity Read ↗

Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancerSemantic proximity Read ↗

Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature ReviewSemantic proximity Read ↗

In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.Semantic proximity Read ↗

Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.